These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 25115992)

  • 1. Bivalirudin versus unfractionated heparin for residual thrombus burden: a frequency-domain optical coherence tomography study.
    Vergallo R; Joye R; Barlis P; Jia H; Tian J; Soeda T; Minami Y; Hu S; Dauerman HL; Toma C; Chan J; Lee H; Biasucci LM; Crea F; Jang IK
    Catheter Cardiovasc Interv; 2015 Mar; 85(4):575-82. PubMed ID: 25115992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of residual thrombus burden in patients with ST-segment elevation myocardial infarction undergoing bivalirudin versus unfractionated heparin infusion: The MATRIX (minimizing adverse hemorrhagic events by transradial access site and angioX) OCT study.
    Garcia-Garcia HM; Adamo M; Soud M; Yacob O; Picchi A; Sardella G; Frigoli E; Limbruno U; Rigattieri S; Diletti R; Boccuzzi G; Zimarino M; Contarini M; Russo F; Calabrò P; Andò G; Varbella F; Garducci S; Palmieri C; Briguori C; Karagiannis A; Valgimigli M
    Catheter Cardiovasc Interv; 2020 Nov; 96(6):1156-1171. PubMed ID: 31883294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of thrombus formation inside the stent during PCI.
    Topaz O
    Catheter Cardiovasc Interv; 2015 Mar; 85(4):583-4. PubMed ID: 25702908
    [No Abstract]   [Full Text] [Related]  

  • 4. Bivalirudin versus heparin with primary percutaneous coronary intervention.
    Venetsanos D; Lawesson SS; James S; Koul S; Erlinge D; Swahn E; Alfredsson J
    Am Heart J; 2018 Jul; 201():9-16. PubMed ID: 29910059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of bivalirudin on post-procedural epicardial blood flow, risk of stent thrombosis and mortality after percutaneous coronary intervention.
    Fiedler KA; Ndrepepa G; Schulz S; Floh S; Hoppmann P; Kufner S; Bernlochner I; Byrne RA; Schunkert H; Laugwitz KL; Kastrati A
    EuroIntervention; 2016 Feb; 11(11):e1275-82. PubMed ID: 26865445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antithrombotic efficacy of bivalirudin compared to unfractionated heparin during percutaneous coronary intervention for acute coronary syndrome.
    Frere C; Laine M; Lemesle G; Morange PE; Paganelli F; Dignat-George F; Resseguier N; Guieu R; Camoin-Jau L; Bonello L
    Platelets; 2019; 30(1):105-111. PubMed ID: 29172822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of bivalirudin compared with unfractionated heparin plus abciximab on infarct size and myocardial recovery after primary percutaneous coronary intervention: the horizons-AMI CMRI substudy.
    Wöhrle J; Merkle N; Kunze M; Cristea E; Mehran R; Rottbauer W; Stone GW
    Catheter Cardiovasc Interv; 2012 Jun; 79(7):1083-9. PubMed ID: 22162175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in high-risk patients undergoing percutaneous coronary intervention (from the Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty-Bivalirudin vs Heparin study).
    Patti G; Pasceri V; D'Antonio L; D'Ambrosio A; Macrì M; Dicuonzo G; Colonna G; Montinaro A; Di Sciascio G
    Am J Cardiol; 2012 Aug; 110(4):478-84. PubMed ID: 22583760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of bivalirudin in patients with diabetes mellitus undergoing percutaneous coronary intervention in current clinical practice.
    Kim LK; Wong SC; Minutello RM; Bergman G; Feldman DN
    J Invasive Cardiol; 2010 Mar; 22(3):94-100. PubMed ID: 20197573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of bivalirudin for percutaneous coronary intervention with rotational atherectomy.
    Delhaye C; Wakabayashi K; Maluenda G; Ben-Dor I; Torguson R; Xue Z; Suddath WO; Satler LF; Pichard AD; Kent KM; Lindsay J; Waksman R
    J Interv Cardiol; 2010 Jun; 23(3):223-9. PubMed ID: 20636842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bleeding after percutaneous coronary intervention with Bivalirudin or unfractionated Heparin and one-year mortality.
    Ndrepepa G; Schulz S; Keta D; Mehilli J; Birkmeier A; Massberg S; Laugwitz KL; Neumann FJ; Seyfarth M; Berger PB; Schömig A; Kastrati A
    Am J Cardiol; 2010 Jan; 105(2):163-7. PubMed ID: 20102912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of bivalirudin in percutaneous coronary intervention following thrombolytic therapy.
    Sardi GL; Lindsay J; Waksman R
    Catheter Cardiovasc Interv; 2013 Oct; 82(4):614-20. PubMed ID: 22581418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndrome initially treated with fondaparinux: results from an international, multicenter, randomized pilot study (SWITCH III).
    Waksman R; Bertrand O; Driesman M; Gruberg L; Rossi J; Mehta S; Swymelar S; Dvir D; Xue Z; Torguson R
    J Interv Cardiol; 2013 Apr; 26(2):107-13. PubMed ID: 23240743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis of randomized clinical trials comparing bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention and in patients with ST-segment elevation myocardial infarction.
    Nairooz R; Sardar P; Amin H; Swaminathan RV; Kim LK; Chatterjee S; Feldman DN
    Am J Cardiol; 2014 Jul; 114(2):250-9. PubMed ID: 24890986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes.
    Feldman DN; Minutello RM; Bergman G; Moussa I; Wong SC
    Catheter Cardiovasc Interv; 2010 Oct; 76(4):513-24. PubMed ID: 20882655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bivalirudin inhibits periprocedural platelet function and tissue factor expression of human smooth muscle cells.
    Pepke W; Eisenreich A; Jaster M; Ayral Y; Bobbert P; Mayer A; Schultheiss HP; Rauch U
    Cardiovasc Ther; 2013 Apr; 31(2):115-23. PubMed ID: 22212466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of residual intrastent thrombus during primary angioplasty: insights from the COCTAIL II study.
    Gatto L; Romagnoli E; Versaci F; Limbruno U; Pawlowski T; Porto I; Marco V; Di Vito L; Imola F; Cremonesi A; Prati F
    J Cardiovasc Med (Hagerstown); 2017 May; 18(5):348-353. PubMed ID: 28212135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of patient outcomes with bivalirudin versus unfractionated heparin in percutaneous coronary intervention.
    Watson K; Seybert AL; Saul MI; Lee JS; Kane-Gill SL
    Pharmacotherapy; 2007 May; 27(5):647-56. PubMed ID: 17461699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does Residual Thrombus After Aspiration Thrombectomy Affect the Outcome of Primary PCI in Patients With ST-Segment Elevation Myocardial Infarction?: An Optical Coherence Tomography Study.
    Higuma T; Soeda T; Yamada M; Yokota T; Yokoyama H; Izumiyama K; Nishizaki F; Minami Y; Xing L; Yamamoto E; Lee H; Okumura K; Jang IK
    JACC Cardiovasc Interv; 2016 Oct; 9(19):2002-2011. PubMed ID: 27712735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials.
    Ndrepepa G; Neumann FJ; Deliargyris EN; Mehran R; Mehilli J; Ferenc M; Schulz S; Schömig A; Kastrati A; Stone GW
    Circ Cardiovasc Interv; 2012 Oct; 5(5):705-12. PubMed ID: 23048052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.